Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs: 755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

mipomersen

IONIS PHARMACEUTICALS INC

Metabolic Diseases

phase 2 small molecule completed

1 trial
non-preserved sterile liquid formulation

Lacuna Pharma Pty Ltd

Type 2 diabetes and Obesity

phase 2 small molecule active

1 trial
rencofilstat, 75 mg

Hepion Pharmaceuticals

NASH With Fibrosis

phase 2 small molecule completed

1 trial
saxagliptin

KYOWA KIRIN AUSTRALIA PTY LTD

Diabetes, Type 2

phase 2 small molecule completed

1 trial
tauroursodeoxycholic acid (TUDCA)

The First People's Hospital of Lianyungang

Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development

phase 2 small molecule active

1 trial
14028 injection

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Type 2 Diabetes

phase 1 mab completed

1 trial
300 mg LX4211 (150 mg tablets)

LEXICON PHARMACEUTICALS, INC.

Type 2 Diabetes Mellitus

phase 1 small molecule completed

1 trial
400 mg LX4211

LEXICON PHARMACEUTICALS, INC.

Type 2 Diabetes Mellitus

phase 1 small molecule completed

1 trial
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus

AstraZeneca AB

Type 2 Diabetes Mellitus

phase 1 other active

1 trial
A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity

Elan Pharma International

Adults Living with Overweight and Obesity

phase 1 other active

1 trial
A Phase I Randomized, Single-center, Double-blind, Two-period Crossover Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Icodec in Participants with Type 2 Diabetes.

Lacuna Pharma Pty Ltd

Type 2 Diabetes Mellitus

phase 1 other active

1 trial
A Phase I, Randomised, Investigator- and Participant-blinded, Placebo-Controlled, Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Obesity.

AstraZeneca AB

Cardiorenal disease

phase 1 other active

1 trial
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389

Lacuna Pharma Pty Ltd

Obesity / Right heart failure (healthy participants)

phase 1 other active

1 trial
A Study of LY4057996 in Healthy Participants and Participants with Type 1 and Type 2 Diabetes (YKAA)

Eli Lilly Co.

Healthy, Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

phase 1 other active

1 trial
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus.

Eli Lilly Co.

Type 1 Diabetes Mellitus

phase 1 other active

1 trial
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity

Hoffmann-La Roche

Type 2 Diabetes Mellitus (T2DM) and overweight or obesity

phase 1 other active

1 trial
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Eli Lilly Co.

Diabetes Mellitus

phase 1 other active

1 trial
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

Eli Lilly Co.

Type 2 Diabetes Mellitus

phase 1 other active

1 trial
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults

Pfizer Australia Pty Ltd

Type 2 Diabetes Mellitus, Obesity, Overweight management

phase 1 other active

1 trial
A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes

Hoffmann-La Roche

Not Applicable

phase 1 other active

1 trial
A Study to Understand What the Body Does to the Study Medicine Called PF-07976016 When Taken by Healthy Adults

Pfizer Australia Pty Ltd

Obesity, Overweight

phase 1 other active

1 trial
A Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Degludec and Insulin Icodec in Participants with Type 2 Diabetes

Lacuna Pharma Pty Ltd

Type 2 Diabetes Mellitus

phase 1 other active

1 trial
A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at steady state in participants with Type 1 Diabetes

Lacuna Pharma Pty Ltd

Type 1 diabetes Mellitus

phase 1 other active

1 trial
A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

NovoThirteen

Cardiometabolic diseases

phase 1 other active

1 trial
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects

Dr. Falk Pharma GmbH

Idiopathic or diabetic gastroparesis

phase 1 other active

1 trial
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers

Lacuna Pharma Pty Ltd

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

phase 1 other active

1 trial
A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function

NovoThirteen

Type 2 Diabetes Mellitus

phase 1 other active

1 trial
A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity

NovoThirteen

Type 2 diabetes mellitus

phase 1 other active

1 trial
A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

NovoThirteen

Type I diabetes

phase 1 other active

1 trial
A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity

NovoThirteen

Participants with obesity, but otherwise healthy

phase 1 other active

1 trial
A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity

NovoThirteen

Obesity

phase 1 other active

1 trial
A research study looking into the effect of NNC05190130 on blood levels of a birth control pill and emptying of the stomach in women after menopause

NovoThirteen

Healthy postmenopausal females (Type 2 Diabetes)

phase 1 other active

1 trial
A research study of a new medicine (NNC0650-0013) in healthy men

NovoThirteen

Weight management, Diabetes mellitus type 2; healthy subjects

phase 1 other active

1 trial
A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes

NovoThirteen

Type 1 diabetes mellitus

phase 1 other active

1 trial
A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes

NovoThirteen

Diabetes type 1

phase 1 other active

1 trial
A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes

NovoThirteen

Healthy Participants and Participants with type 2 diabetes

phase 1 other active

1 trial
A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or without type 2 diabetes

NovoThirteen

Obesity, Type 2 Diabetes with either overweight or obesity

phase 1 other active

1 trial
A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity

NovoThirteen

obesity

phase 1 other active

1 trial
A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

NovoThirteen

Healthy participants and participants with type 2 diabetes

phase 1 other active

1 trial
A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight

NovoThirteen

Obesity

phase 1 other active

1 trial
A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo

NovoThirteen

Obesity

phase 1 other active

1 trial
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated tablets (Polfa Tarchomin S.A., Poland) versus Froxiga 10 mg film-coated tablets (AstraZeneca AB, Sweden) in healthy volunteers under fasting conditions.

Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

intended for treatment of for the treatment of (2): • insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. • symptomatic chronic heart failure. • chronic kidney disease.

phase 1 other active

1 trial
A study comparing the new drug PG413 produced by Celon Pharma SA with the drug Eliquis available on the market in healthy volunteers.

Lacuna Pharma Pty Ltd

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

phase 1 other active

1 trial
A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector

Boehringer Ingelheim

Healthy volunteer trial

phase 1 other active

1 trial
A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector

Boehringer Ingelheim

Healthy volunteer trial

phase 1 other active

1 trial
A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver

Boehringer Ingelheim

No targeted indication. Male and female subjects with obesity.

phase 1 other active

1 trial
A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity

Boehringer Ingelheim

Obesity

phase 1 other active

1 trial
A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

Hoffmann-La Roche

Type 2 Diabetes and obesity

phase 1 other active

1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

mipomersen

non-preserved sterile liquid formulation

rencofilstat, 75 mg

saxagliptin

tauroursodeoxycholic acid (TUDCA)

14028 injection

300 mg LX4211 (150 mg tablets)

400 mg LX4211

A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus

A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity

A Phase I Randomized, Single-center, Double-blind, Two-period Crossover Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Icodec in Participants with Type 2 Diabetes.

A Phase I, Randomised, Investigator- and Participant-blinded, Placebo-Controlled, Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Obesity.

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389

A Study of LY4057996 in Healthy Participants and Participants with Type 1 and Type 2 Diabetes (YKAA)

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus.

A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults

A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes

A Study to Understand What the Body Does to the Study Medicine Called PF-07976016 When Taken by Healthy Adults

A Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Degludec and Insulin Icodec in Participants with Type 2 Diabetes

A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at steady state in participants with Type 1 Diabetes

A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers

A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function

A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity

A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity

A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity

A research study looking into the effect of NNC05190130 on blood levels of a birth control pill and emptying of the stomach in women after menopause

A research study of a new medicine (NNC0650-0013) in healthy men

A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes

A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes

A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes

A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or without type 2 diabetes

A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity

A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight

A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo

A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated tablets (Polfa Tarchomin S.A., Poland) versus Froxiga 10 mg film-coated tablets (AstraZeneca AB, Sweden) in healthy volunteers under fasting conditions.

A study comparing the new drug PG413 produced by Celon Pharma SA with the drug Eliquis available on the market in healthy volunteers.

A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector

A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector

A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver

A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity

A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

Frequently asked questions

Stay Ahead in Pharma